Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:6
|
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源
LIPIDS IN HEALTH AND DISEASE | 2015年 / 14卷
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] The metabolic syndrome as predictor of coronary heart disease, all-cause mortality and insulin resistance - the influence of choice of criteria
    Zethelius, B.
    Jensevik, K.
    Berglund, L.
    Berne, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 66 - 66
  • [42] THE FREQUENCY AND PREVALENCE OF THE CORONARY HEART DISEASE IN PATIENTS WITH METABOLIC SYNDROME
    Cakmak, H. Altug
    Karadag, N.
    Karadag, B.
    Cosansu, K.
    Ongen, Z.
    Vural, V. A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 166 - 167
  • [43] Association between insulin resistance and metabolic syndrome risk factors in Japanese
    Yamada, Chizumi
    Moriyama, Kengo
    Takahashi, Eiko
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (02) : 185 - 190
  • [44] Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors
    Kajikawa, Yutaka
    Ikeda, Masae
    Takemoto, Shunji
    Tomoda, Jun
    Ohmaru, Natsuki
    Kusachi, Shozo
    INTERNATIONAL HEART JOURNAL, 2011, 52 (01) : 17 - 22
  • [45] Novel Metabolic Syndrome Index Is a Useful Biomarker for Coronary Heart Disease Risk Prediction and Diagnosis of the Metabolic Syndrome
    Abdella, Nabilla
    Mojiminiyi, Olusegun A.
    DIABETES, 2013, 62 : A123 - A123
  • [46] The metabolic syndrome in a population with coronary heart disease
    Hernandez-Mijares, A
    Riera, C
    Sola, E
    Martinez-Triguero, ML
    Morillas, C
    Garzon, S
    DIABETES, 2003, 52 : A155 - A156
  • [47] Metabolic syndrome, diabetes and coronary heart disease
    Haffner, SM
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 31 - 37
  • [48] Metabolic syndrome, insulin resistance, and coronary artery calcifcation
    Reilly, MP
    Wolfe, ML
    Myers, EC
    Rader, DJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (05) : A57 - A58
  • [49] Metabolic syndrome potentiates the risk of coronary heart disease in patients with type 2 diabetes
    Bianchi, C
    Penno, G
    Carciato, F
    Giovannitti, GM
    Malloggi, L
    Pancani, F
    Di Canni, G
    Del Pato, S
    Miccoli, R
    DIABETES, 2005, 54 : A591 - A591
  • [50] Does the metabolic syndrome increase mortality and stroke risk in coronary heart disease patients?
    Goldbourt, U
    Boyko, V
    Koren-Morag, N
    Tanne, D
    CIRCULATION, 2005, 111 (14) : E203 - E203